Key Takeaways Incyte shares sank Monday after the drugmaker released the latest data from a clinical trial.The drug, ...

Shares of vTv Therapeutics rose after the Food and Drug Administration lifted a clinical hold on its diabetes treatment program. The stock gained 40% to $20.78 Monday morning. Shares have climbed ...

Incyte (Nasdaq: INCY) today announced positive topline results from its pivotal Phase 3 STOP-HS clinical trial program evaluating the safety and efficacy of povorcitinib (INCB054707), an oral ...

Another company involved in using AI to repurpose failed drugs – as well as drugs that have already been approved – is ...

Cadisegliatin, which was paused in the third phase of its CATT1 trial, is taken orally and is designed to target the liver specifically and aims to treat diabetes by improving blood sugar control. VTv ...

Cadisegliatin has the potential to be the first oral adjunct therapy for type 1 diabetesCATT1 Phase 3 trial expected to resume following ...

Despite being a mainstay of Parkinson's disease treatment, levodopa, a dopamine-replenishing medication, can cause nasty side ...

The owners of a Pembroke Pines-based medical research facility pleaded guilty Monday to charges they faked information around ...

National MS Education and Awareness Month is celebrated each year in the US in March, after having been launched in 2003 by ...

A new study found that fair prices for medications like Wegovy and Zepbound would be hundreds less per month than they are ...

Genetic testing is transforming depression treatment by tailoring antidepressants to your DNA for better results and fewer ...

Multiracial growth impacts clinical trials. Explore challenges in race classification, health disparities, and genomic profiling.